Last €0.63 EUR
Change Today 0.00 / 0.00%
Volume 610.1K
As of 11:35 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

diaxonhit (ALEHT) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/17/13 - €1.20
52 Week Low
12/12/13 - €0.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAXONHIT (ALEHT)

Related News

No related news articles were found.

diaxonhit (ALEHT) Related Businessweek News

No Related Businessweek News Found

diaxonhit (ALEHT) Details

Diaxonhit discovers and commercializes specialty diagnostic products in the transplantation, infectious diseases, and cancer diagnosis specialty areas. Its commercialized product includes Tétanos Quick Stick, a proprietary test, which is used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products comprise the BJI InoPlex kit, a test that allows the detection of infections linked to articular prosthesis; and EHT Dx15, a test for the diagnosis of thyroid cancer, as well as licensed product includes AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. It is also involved in the development of companion diagnostics for resistant and breast cancers; and tests to monitor the direct effect of drug activity. Diaxonhit was founded in 1997 and is headquartered in Paris, France.

Founded in 1997

diaxonhit (ALEHT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

diaxonhit (ALEHT) Key Developments

Diaxonhit Announces Consolidated Revenue Results for the Mid-Year Ended June 30, 2014

Diaxonhit announced consolidated revenue results for the mid-year ended June 30, 2014. For the period, the company reported consolidated turnover of EUR 15.9 million, an increase of 2% compared to consolidated turnover of EUR 15.6 million as of June 30, 2013.

Diaxonhit Announces Consolidated Earnings Results for the Year Ended on December 31, 2013

Diaxonhit announced consolidated earnings results for the year ended on December 31, 2013. For the year, the company reported total revenues of EUR 31.216 million against EUR 5.387 million a year ago. Loss from operations was EUR 6.775 million against EUR 6.474 million a year ago. Loss before tax and amortization of goodwill was EUR 6.881 million against EUR 6.643 million a year ago. Net loss was EUR 5.994 million or EUR 0.11 per diluted share against EUR 5.770 million or EUR 0.16 per diluted share year ago. Net cash used in operations was EUR 4.901 million against EUR 4.447 million a year ago. Purchase of property and equipment was EUR 0.574 million against EUR 0.087 million a year ago.

Diaxonhit, Annual General Meeting, Jun 19, 2014

Diaxonhit, Annual General Meeting, Jun 19, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALEHT:FP €0.63 EUR 0.00

ALEHT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DiaGenic ASA 0.90 NOK -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation ALEHT Industry Range
No financial data is available for ALEHT.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAXONHIT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at